Strs Ohio acquired a new stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) during the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 1,117 shares of the biopharmaceutical company’s stock, valued at approximately $141,000.

Several other large investors have also recently bought and sold shares of ALNY. Orbimed Advisors LLC boosted its stake in shares of Alnylam Pharmaceuticals by 69.7% in the 3rd quarter. Orbimed Advisors LLC now owns 1,084,800 shares of the biopharmaceutical company’s stock valued at $127,453,000 after purchasing an additional 445,600 shares during the last quarter. Kornitzer Capital Management Inc. KS bought a new stake in shares of Alnylam Pharmaceuticals in the 3rd quarter valued at $19,131,000. First Trust Advisors LP boosted its stake in shares of Alnylam Pharmaceuticals by 25.3% in the 3rd quarter. First Trust Advisors LP now owns 784,619 shares of the biopharmaceutical company’s stock valued at $92,185,000 after purchasing an additional 158,288 shares during the last quarter. WINTON GROUP Ltd bought a new stake in shares of Alnylam Pharmaceuticals in the 3rd quarter valued at $10,633,000. Finally, Dimensional Fund Advisors LP boosted its stake in shares of Alnylam Pharmaceuticals by 59.1% in the 2nd quarter. Dimensional Fund Advisors LP now owns 179,429 shares of the biopharmaceutical company’s stock valued at $14,311,000 after purchasing an additional 66,651 shares during the last quarter. 88.59% of the stock is currently owned by institutional investors.

A number of equities research analysts have recently commented on ALNY shares. B. Riley started coverage on shares of Alnylam Pharmaceuticals in a research note on Wednesday, November 1st. They issued a “buy” rating and a $240.00 price objective on the stock. FBR & Co initiated coverage on shares of Alnylam Pharmaceuticals in a research report on Monday, October 30th. They set a “buy” rating and a $150.00 target price on the stock. Needham & Company LLC reiterated a “buy” rating and set a $152.00 target price (up previously from $125.00) on shares of Alnylam Pharmaceuticals in a research report on Friday, November 3rd. Piper Jaffray Companies reiterated a “buy” rating and set a $182.00 target price on shares of Alnylam Pharmaceuticals in a research report on Friday, November 17th. Finally, Cowen reiterated a “buy” rating and set a $151.00 target price on shares of Alnylam Pharmaceuticals in a research report on Thursday, November 9th. Three equities research analysts have rated the stock with a sell rating, seven have assigned a hold rating, fifteen have given a buy rating and one has given a strong buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus target price of $126.98.

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) opened at $119.26 on Wednesday. The company has a debt-to-equity ratio of 0.14, a quick ratio of 9.83 and a current ratio of 9.83. Alnylam Pharmaceuticals, Inc. has a 1-year low of $44.50 and a 1-year high of $147.63. The firm has a market cap of $11,694.81, a price-to-earnings ratio of -22.04 and a beta of 2.69.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its quarterly earnings data on Thursday, February 8th. The biopharmaceutical company reported ($1.48) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.38) by ($0.10). Alnylam Pharmaceuticals had a negative return on equity of 48.88% and a negative net margin of 545.95%. The business had revenue of $37.90 million for the quarter, compared to analyst estimates of $19.31 million. During the same quarter in the previous year, the company posted ($1.32) EPS. The business’s quarterly revenue was up 116.6% on a year-over-year basis. equities analysts forecast that Alnylam Pharmaceuticals, Inc. will post -6.23 EPS for the current year.

In other news, CEO John Maraganore sold 73,415 shares of the stock in a transaction dated Wednesday, November 22nd. The shares were sold at an average price of $130.90, for a total value of $9,610,023.50. Following the completion of the sale, the chief executive officer now owns 223,125 shares in the company, valued at $29,207,062.50. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, VP Michael Mason sold 36,745 shares of the stock in a transaction dated Thursday, January 4th. The shares were sold at an average price of $131.59, for a total transaction of $4,835,274.55. Following the completion of the sale, the vice president now owns 6,352 shares of the company’s stock, valued at approximately $835,859.68. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 146,409 shares of company stock worth $19,279,377. Corporate insiders own 4.30% of the company’s stock.

WARNING: “Strs Ohio Takes $141,000 Position in Alnylam Pharmaceuticals, Inc. (ALNY)” was originally posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this report on another website, it was illegally stolen and reposted in violation of U.S. and international trademark and copyright law. The correct version of this report can be read at https://www.thecerbatgem.com/2018/02/14/strs-ohio-takes-141000-position-in-alnylam-pharmaceuticals-inc-alny.html.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs).

Institutional Ownership by Quarter for Alnylam Pharmaceuticals (NASDAQ:ALNY)

Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.